624 related articles for article (PubMed ID: 16320349)
1. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.
Levy Y; Shenkman B; Tamarin I; Pauzner R; Shoenfeld Y; Langevitz P; Savion N; Varon D
Arthritis Rheum; 2005 Dec; 52(12):4011-7. PubMed ID: 16320349
[TBL] [Abstract][Full Text] [Related]
2. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells.
Goldschmidt N; Spectre G; Brill A; Zelig O; Goldfarb A; Rachmilewitz E; Varon D
Thromb Haemost; 2008 Nov; 100(5):864-70. PubMed ID: 18989531
[TBL] [Abstract][Full Text] [Related]
3. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies.
Jy W; Tiede M; Bidot CJ; Horstman LL; Jimenez JJ; Chirinos J; Ahn YS
Thromb Res; 2007; 121(3):319-25. PubMed ID: 17582471
[TBL] [Abstract][Full Text] [Related]
4. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions.
Zwaginga JJ; Koomans HA; Sixma JJ; Rabelink TJ
J Clin Invest; 1994 Jan; 93(1):204-11. PubMed ID: 8282789
[TBL] [Abstract][Full Text] [Related]
5. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis.
Kaplanski G; Cacoub P; Farnarier C; Marin V; Grégoire R; Gatel A; Durand JM; Harlé JR; Bongrand P; Piette JC
Arthritis Rheum; 2000 Jan; 43(1):55-64. PubMed ID: 10643700
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation.
Campbell AL; Pierangeli SS; Wellhausen S; Harris EN
Thromb Haemost; 1995 Mar; 73(3):529-34. PubMed ID: 7667838
[TBL] [Abstract][Full Text] [Related]
7. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome.
Robbins DL; Leung S; Miller-Blair DJ; Ziboh V
J Rheumatol; 1998 Jan; 25(1):51-6. PubMed ID: 9458202
[TBL] [Abstract][Full Text] [Related]
8. Patients with antiphospholipid syndrome display endothelial perturbation.
Cugno M; Borghi MO; Lonati LM; Ghiadoni L; Gerosa M; Grossi C; De Angelis V; Magnaghi G; Tincani A; Mari D; Riboldi P; Meroni PL
J Autoimmun; 2010 Mar; 34(2):105-10. PubMed ID: 19656656
[TBL] [Abstract][Full Text] [Related]
9. Distribution of lupus anticoagulant and anticardiolipin antibody isotypes in a population with antiphospholipid syndrome.
Guglielmone HA; Fernandez EJ
J Rheumatol; 1999 Jan; 26(1):86-90. PubMed ID: 9918246
[TBL] [Abstract][Full Text] [Related]
10. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.
Armstrong PC; Dhanji AR; Truss NJ; Zain ZN; Tucker AT; Mitchell JA; Warner TD
Thromb Haemost; 2009 Oct; 102(4):772-8. PubMed ID: 19806265
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.
Girón-González JA; García del Río E; Rodríguez C; Rodríguez-Martorell J; Serrano A
J Rheumatol; 2004 Aug; 31(8):1560-7. PubMed ID: 15290736
[TBL] [Abstract][Full Text] [Related]
12. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
[TBL] [Abstract][Full Text] [Related]
13. Familial lupus anticoagulant.
Tănăseanu C; Tănăseanu S
Roum Arch Microbiol Immunol; 1999; 58(3-4):259-65. PubMed ID: 11845463
[TBL] [Abstract][Full Text] [Related]
14. Platelet function in patients with lupus anticoagulant and thrombosis.
Diez-Ewald M; Torres-Guerra E; Vizcaíno G; Arteaga-Vizcaíno M
Invest Clin; 1995 Mar; 36(1):13-21. PubMed ID: 7779940
[TBL] [Abstract][Full Text] [Related]
15. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
Ames PR; Pyke S; Iannaccone L; Brancaccio V
Thromb Haemost; 1995 May; 73(5):768-73. PubMed ID: 7482401
[TBL] [Abstract][Full Text] [Related]
17. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system.
Reverter JC; Tàssies D; Escolar G; Font J; López Soto A; Ingelmo M; Ordinas A
Thromb Haemost; 1995 Jan; 73(1):132-7. PubMed ID: 7740485
[TBL] [Abstract][Full Text] [Related]
18. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
Mayr FB; Knöbl P; Jilma B; Siller-Matula JM; Wagner PG; Schaub RG; Gilbert JC; Jilma-Stohlawetz P
Transfusion; 2010 May; 50(5):1079-87. PubMed ID: 20070617
[TBL] [Abstract][Full Text] [Related]
19. [Antiphospholipid syndrome and stroke].
Kitagawa Y
Rinsho Shinkeigaku; 2005 Nov; 45(11):852-5. PubMed ID: 16447744
[TBL] [Abstract][Full Text] [Related]
20. Prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholipid syndrome.
Urbanus RT; de Laat HB; de Groot PG; Derksen RH
Arthritis Rheum; 2004 Nov; 50(11):3605-9. PubMed ID: 15529374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
